timothy sykes logo
TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat Thumbnail
G Google News

TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat

JACK KELLOGG•UPDATED AUG. 8, 2026, 11:07 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

10x Genomics Inc. stocks have been trading up by 13.62 percent amid strong investor optimism over its latest product advancements.

What Traders Need To Know

  • Q2 2026 revenue came in at $151M, slightly above expectations and about 3% higher year over year when excluding one-off patent settlement revenue.
  • The company posted a Q2 loss of $0.14 per share, better than the expected $0.24 loss but down from a profit a year ago.
  • Management nudged 2026 revenue guidance to $610M–$630M, now a bit ahead of Street expectations around $613.7M.
  • Stifel doubled its price target to $50 with a Buy rating, while Citi and Morgan Stanley also raised targets to $50 and $40, though they stayed Neutral/Equal Weight.
  • Management highlighted strong early demand for the Atera platform, closed the Proteintech Genomics deal, and signed a multi-year cancer research collaboration with Lausanne University Hospital.

Candlestick Chart

Weekly Update Aug 03 – Aug 07, 2026: On Saturday, August 08, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 13.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

10x Genomics occupies a leading position in single-cell and spatial biology with high-quality fundamentals but currently subscale profitability. Revenue of ~$643M with 6–14% multi‑year CAGRs and a 69.6% gross margin underscore a premium consumables model, yet EBIT margin (-3%) and ROIC remain negative, reflecting heavy R&D and SG&A. Balance sheet strength is clear: minimal leverage (total debt/equity 0.1), ample liquidity (current ratio 5.9, >$500M cash), and consistently positive free cash flow, albeit at a rich ~9x sales and ~55x cash flow.

Technically, TXG has shifted from range-bound consolidation into a sharp upside breakout. This week’s move from roughly $47 to a $52.25 high, with a strong close at $51.81 and expanding intraday ranges, indicates aggressive buying and short-covering. Five‑minute candles show sustained bid support on pullbacks rather than fast reversals, consistent with institutional accumulation. The dominant trend is now short- to medium-term bullish; $47–48 is the first critical support zone, with $48 as an actionable stop‑level for new longs initiated near current prices.

Fundamentally, TXG is outgrowing most Healthcare and broader Life Science Tools peers, albeit at a higher valuation and with biotech‑like earnings volatility. Q2 beat on revenue and EPS, a guidance lift to $610–630M, Atera traction, and CHUV collaboration reinforce durable multiomics demand, while multiple banks have raised targets to ~$40–50. With the multiomics market projected at 12%+ CAGR and TXG’s improving gross margin (mid‑70s), a 6–12 month upside target range of $58–62 is justified, with resistance near $55 and firm support at $47.

More Breaking News

Quick Financial Overview

10x Genomics Inc. (TXG) is still in growth mode, not profit mode. Q2 2026 revenue of $151M beat consensus and, adjusted for prior patent settlements, grew roughly 3% versus last year. Gross margin is strong at 74%, showing the core business has healthy unit economics even as the company reports a net loss of about $17.9M for the quarter. For traders, that mix of modest growth, high gross margin, and red bottom line means the stock will trade like a higher-beta growth name rather than a steady compounder.

The guidance raise to $610M–$630M for 2026, slightly above the ~$614M Street view, signals cautious confidence from 10x Genomics Inc. management. On the balance sheet, TXG carries very little debt, with long-term debt at about $66.8M against $502.5M in cash and a current ratio near 5.9, so liquidity risk is low. Cash flow is improving, with positive operating cash flow of $16.97M and free cash flow of $15.39M, backed by stock-based compensation and tight working-capital management.

On the chart, TXG just saw a sharp volatility spike. The weekly data show a drop from the mid-$40s to an intraday low near $42.70, followed by a snapback to close above $51, reflecting a fast bullish reversal after the earnings dip. Intraday, the 5‑minute snapshot captures a drive from the mid-$40s to above $52, signaling aggressive dip-buying after the initial 3% after-hours selloff. With that kind of range expansion, traders should expect wide intraday swings as the market digests the EPS beat, higher guidance, and upbeat analyst price targets around $40–$50.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”